Replies to post #28559 on Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

PL, reasonable and thoughtful response as usual, my friend.
What is becoming an investment reality issue us this... looking into your Q2,'20, the share price is low range bound for over year. That is " dead money" and some to many will look at " lost opportunity" costs and " walk."
The company has sought and hired high priced talent... I would have expect a lot more in "action and goal setting." The company has to become more than science and cash flow sensitive, but also now much more... shareholder sensitive. I'd bet that some of the bigger holders of shares know to make use of capital and dislike no movement. Yes, my opinion, but I have others thinking the same... Peter, look at a larger picture, please.

[Tripolar]

Assuming the data continues to impress, I would think the share price would be at least in the $7 range by year's end. The best option for all share holders would be for the warrant holders to convert their 23 M warrants into shares. This would give Marker just over $100 M and should be enough to fund operations thru at least the middle of 2021. It's possible a BP partner could be on board by this time, providing more cash for operations.